Nixon, Andrew B.

HDAC6 is a microtubule-associated deacetylase

Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature

Microtubule and mitosis dynamicsHistone Deacetylase Inhibitors Research

Cited by 2,403

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy

Immunotherapy and Immune ResponsesAngiogenesis and VEGF in Cancer

Cited by 311

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 220

NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health.

SenNet Consortium, Writing Group, Lee, P. J., Benz, C. C., Blood, P., Börner, K., Campisi, J., Chen, F., Daldrup-Link, H., De Jager, P., et al. (2022) · Nature Aging

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 122

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Mettu, N. B., Twohy, E., Ou, F.-S., Halfdanarson, T. R., Lenz, H. J., Breakstone, R., Boland, P. M., Crysler, O., Wu, C., Grothey, A., et al. (2019) · Annals of Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 72

Association of Coffee Intake with Survival in Patients With Advanced or Metastatic Colorectal Cancer

Mackintosh, C., Yuan, C., Ou, F.-S., Zhang, S., Niedzwiecki, D., Chang, I.-W., O’Neil, B. H., Mullen, B. C., Lenz, H.-J., Blanke, C. D., et al. (2020) · JAMA Oncology

Coffee research and impactsColorectal Cancer Treatments and Studies

Cited by 52

Single-cell and spatial detection of senescent cells using DeepScence

Qu, Y., Ji, B., Dong, R., Gu, L., Chan, C., Xie, J., Glass, C., Wang, X.-F., Nixon, A. B., & Ji, Z. (2025) · Cell Genomics

Single-cell and spatial transcriptomicsTelomeres, Telomerase, and Senescence

Cited by 30

Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer

Seligmann, J. F., Hatch, A. J., Richman, S. D., Elliott, F., Jacobs, B., Brown, S., Hurwitz, H., Barrett, J. H., Quirke, P., Nixon, A. B., et al. (2018) · JAMA Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 25

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., et al. (2019) · Cancer Chemotherapy and Pharmacology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 18

Correlation of Imaging and Plasma Based Biomarkers to Predict Response to Bevacizumab in Epithelial Ovarian Cancer (EOC)

Buechel, M. E., Enserro, D., Burger, R. A., Brady, M. F., Wade, K., Secord, A. A., Nixon, A. B., Mirniaharikandehei, S., Liu, H., Zheng, B., et al. (2021) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentCancer Risks and Factors

Cited by 17